

Aurigene Pharmaceutical Services Ltd., and Vipergeren announce a strategic partnership for offering DNA encoded library (DEL) screening and integrated drug discovery services.

- The partnership aims to accelerate innovation in drug discovery by increasing success rates and reducing timelines through screening a billion+ small-molecule compounds either in a living cell or on a purified drug target protein.
- By combining Aurigene's drug discovery capabilities with Vipergeren's DEL screening technologies, the companies will integrate and enhance their end-to-end discovery solution, by offering expedited hit identification.
- The two companies will also collaborate on advancing DEL technologies.

Hyderabad, India, and Copenhagen, Denmark; April 19, 2024: Aurigene Pharmaceutical Services Ltd. (Aurigene), a global contract research, development, and manufacturing services organization (CRDMO), and Vipergeren ApS, a niche small-molecule drug discovery service provider specialized in DEL technologies, entered into a strategic partnership. The collaboration aims to co-market and offer DEL screening technologies to global customers as a standalone service or as an integrated drug discovery service. The two companies will also co-develop new DELs with an emphasis on novel chemical diversity and drug-likeness to further strengthen their service offering.

Vipergeren's high-fidelity DEL screening technologies would be a strategic addition to Aurigene's existing small molecule discovery capabilities, from compound resynthesis to candidate nomination. With the addition of hit screening capabilities, Aurigene would be able to enhance its Integrated Drug Discovery (IDD) service offering to its global customers.

"The partnership with Vipergeren emphasizes our commitment to accelerating innovation and customer-centric approach. The recent [launch of Aurigene.AI](#) for small molecules and DEL partnership with Vipergeren aim to reduce the hit finding timelines. Vipergeren's proven track record, with more than 90 partnerships with big pharma and biotech companies, and their streamlined hit finding platform, makes Vipergeren the ideal strategic partner for us.", said **Akhil Ravi, CEO, Aurigene.**

"We are excited to partner with Aurigene, a global CRDMO focused on customer service. Aurigene's drug discovery capabilities and global reach makes a perfect match for Vipergeren. I am looking forward to a successful partnership, and to offering our proprietary technologies to global customers.", said **Nils Jakob Vest Hansen, PhD, CEO, Vipergeren.**

About Aurigene:

Aurigene, a Dr. Reddy's Laboratories company, is a global contract research, development, and manufacturing organization (CRDMO built on the legacy of accelerating innovation and backed by a vast experience in drug discovery, development, and manufacturing of small and large molecules. We offer integrated and standalone services for discovery chemistry, biotherapeutics discovery, discovery biology, development and manufacturing services for clinical phase I-III programs, regulatory submission batches and commercial manufacturing.

For more details about Aurigene, please visit www.aurigeneservices.com.

[LinkedIn](#) [YouTube](#)



About Viperger:

Viperger is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Viperger provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan. For more details about Viperger and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.viperger.com.

Contacts:

Aurigene

ContactAPSL@aurigeneservices.com

Viperger

info@viperger.com